Corteva, Inc. (CTVA): what the price assumes

In the published model solve dated 2026-Q2, anchored at $83.90, Corteva, Inc. (CTVA) is priced for today's economics sustained for ~6.5 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/CTVA

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.8% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: n/a

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=9)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Two businesses under one ticker: Seed at $9,898 million of 2025 net sales and Crop Protection at $7,503 million, with corn alone accounting for about 40% of the revenue mix.
• The separation into two standalone public companies, announced October 1, 2025, is tracking for the fourth quarter of 2026, which means the peer set and the capital structure a buyer is underwriting both change before the year is out.
• Second-quarter results land July 30, 2026; first-quarter net sales were $4,905 million against $4,417 million a year earlier, while cost of goods sold barely moved.

Bull Case

Mature is the right label and the wrong lens. Corteva looks like a settled agricultural supplier, and on the surface it is: net sales of $17,401 million in 2025 against $16,908 million the year before, in an industry whose customers are farmers whose acreage does not change much. But the company announced on October 1, 2025 its intent to separate Seed and Crop Protection into "two standalone, publicly traded companies, in a transaction that is intended to be a tax-free spin-off for U.S. federal income tax purposes". That is a mature company being taken apart on purpose, and the reason is that the two halves are not the same kind of business at all.

The seed half is the better one, and 2025 showed it. Seed net sales were $9,898 million, up 4 percent from $9,545 million, and on the company's own segment measure Seed operating EBITDA reached $2,636 million, up 19 percent from $2,219 million, which the filing attributes to commercial execution and market share gains in North America and Brazil. Sales up 4 and segment profit up 19 is what operating leverage looks like in a business where the cost of goods is largely fixed by the previous season's production plan.

That leverage rests on something specific. The Seed segment sells germplasm with advanced traits, and it reaches farmers through what the 10-K describes as a "multi-channel, multi-brand strategy, which includes four differentiated channels: Pioneer agency model, regional seed brands, retail, as well as third" party arrangements. Pioneer's agency model in particular puts a sales agent inside the farming community rather than a distributor between the company and the grower. In a product where the buying decision happens once a year and the consequences last a whole season, the person a farmer trusts is a genuine asset, and it is not one a competitor can buy.

The first quarter of 2026 showed the shape of the gearing. Net sales were $4,905 million against $4,417 million a year earlier, on a 6 percent volume increase, a 4 percent currency benefit and a 1 percent price increase. Cost of goods sold over the same comparison went from $2,342 million to $2,372 million. Nearly the entire increase in sales dropped through as gross profit, because volume through an existing production base costs very little more to supply.

Financing is not a constraint on any of it. Interest expense fell to $180 million in 2025 from $233 million in 2024, on lower short-term borrowings and lower rates. Net borrowing is modest either way it is measured, at roughly 0.5 billion dollars on the funded-debt build or nearer 0.9 billion once leases are included, against a company generating cash and shrinking its share count by about 2% a year over the last four years. A separation is an expensive thing to execute. This balance sheet can pay for one.

Bear Case

Agricultural inputs run on a cycle, and the crop protection half is still on the wrong side of it. Net sales in that segment were $7,503 million in 2025, up 2 percent from $7,363 million, which sounds like a recovery until you notice that 2024 was down 5 percent from $7,754 million in 2023. Two years of decline followed by a partial recovery leaves the business smaller than it was three years ago. Farm economics drive that: when grain prices are low, growers cut the discretionary chemistry first and stretch what is in the shed. Nothing in the segment's results says the cycle has turned rather than paused.

Competition in this half is also structurally different from the seed half. Molecules come off patent, generic manufacturers take the volume, and the incumbent defends price by launching new active ingredients faster than the old ones erode. The 10-K acknowledges the arms race directly, noting that competitors "are also making considerable investments in similar new biotechnology products, improved germplasm products, biological and chemical products and agronomic recommendation products". That is a treadmill, not a moat, and it consumes research spending whether or not the cycle cooperates.

The seed moat has a dependency worth naming too. The filing states that "Most corn hybrids and soybean varieties sold to customers contain biotechnology traits licensed from third parties under these long-term licenses". The germplasm is Corteva's; a good deal of the trait technology inside it is rented. Royalty terms are negotiated, they expire, and the counterparties are the same companies competing for the same acres.

There is a live legal overhang as well. The company discloses "the current FTC and related state attorney general lawsuits pending against Corteva" over competition practices, with the possibility that regulators impose fines, penalties, or restrictions on business practices. Distribution arrangements are exactly what those cases probe, and distribution is where the seed business earns its premium.

Then there is the price itself. Only the forward-growth methods reach it. The peer-multiple methods land about 2.03 times under it, the earnings-power methods about 2.93 times under, and the asset-value methods about 3.36 times under. So the entire case rests on durable compounding that static frames cannot price, and the pace the price assumes runs well above what this company has actually delivered. A separation may well unlock value; it does not by itself deliver a growth rate. And a spin-off is an execution project with its own risk, which the company itself flags in cautioning that the transaction "may not achieve the intended benefits".

Valuation

One company today, two by the end of the year, and that pending split is the most important thing to hold in mind while reading any figure here. The price is a bet on durable compounding, and it has to be, because only the forward-growth methods reach it. The peer-multiple lens sits about 2.03 times below the price. The earnings-power methods, which capitalize what the company earns now without crediting growth, sit about 2.93 times below. The asset-value lens is furthest away at about 3.36 times. When every static frame lands well short and only the method that projects compounding gets there, what is being paid for is durability, and no amount of balance-sheet or book-value analysis will confirm or deny it.

The harder question is which earnings number that durability should be measured against, and here the company's two headline lines sit a long way apart. On the company's own segment measure, operating EBITDA reached $3,848 million in 2025, up from $3,376 million. On the audited line beneath it, income from continuing operations after income taxes was $1,204 million, against $863 million in 2024. The distance between those two figures is depreciation, amortization, restructuring and other significant items, plus tax, and it is not small. The two lines sit more than three times apart, and which one an investor anchors on moves the whole assessment by roughly that much. Both are real figures on their stated bases. The gap is what the separation is partly meant to clarify, since standalone reporting forces each half to show its own version of the same lines.

The peer comparison has the same pending problem, which is why it should be read lightly today. FMC is the natural comparison for the crop protection half and not for the seed half, and the fertilizer producers in the wider cohort, MOS and CF, are a different business entirely, selling a commodity into the same customer. After the split, each successor gets a peer set that actually matches it. Before the split, any whole-company multiple is a blend of a branded-technology business and a chemistry business that the market has never valued the same way.

Solvency does not bound this story tightly, which is unusual and useful. Interest expense was $180 million in 2025, down from $233 million the prior year. Net borrowing is modest on either basis in the accounts, roughly 0.5 billion dollars on the funded-debt build or nearer 0.9 billion counting leases, and the company is not consuming cash. That leaves the outcome resting where it should: on whether the seed franchise compounds after it is standing on its own, and on whether the crop protection cycle turns before or after it has to.

Catalysts

The calendar is the story this year. The separation announced on October 1, 2025 is tracking for the fourth quarter of 2026, and the scaffolding is going up on schedule. Headquarters were named on May 12, 2026, with the crop protection company staying in Indianapolis and the seed and genetics company, to be called Vylor, based in Johnston, Iowa. On June 29, 2026 both boards were announced, with Greg Page as chair of the crop protection company and Karen Grimes as chair of Vylor, and the company reaffirmed the fourth-quarter timing.

Capital return has continued through the process. The board declared a quarterly dividend of 18 cents a share on July 24, 2026, payable September 15. Earlier, on July 3, the company announced a partnership with Arevo covering soy crop nutrition for European growers. Neither is large. Both suggest the operating business is not being run in suspended animation while the lawyers work.

Second-quarter results are scheduled for July 30, 2026. The first quarter set a demanding comparison, with net sales of $4,905 million against $4,417 million and cost of goods sold that barely moved, so the question is whether the volume gains held into the season's second half or simply pulled purchases forward. The other thing to watch is the separation cost line, because the difference between a spin-off that lands on schedule and one that slips is measured in exactly that expense.

Peer Cohorts (Per Segment, With Filing Citations)

Seed / Crop Protection (reported)

• FMC (FMC CORPORATION)
• FY2025 10-K: …We believe that FMC has one of the most productive crop protection pipelines in agriculture. The pipeline is highly valuable because it is biased toward new modes of action. The current R&D pipeline features 16 new active areas in discovery and 19 new active ingredients in development. The growth portfolio includes…
• FY2025 10-K: …us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2023-01-01 2023-12-31 0000037785 us-gaap:SegmentDiscontinuedOperationsMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember…
• MOS (MOSAIC CO)
• FY2025 10-K: …products in order to support domestic employment or other political or social goals. To the extent other producers of crop nutrients enjoy competitive advantages or are willing to accept lower profit levels, the price of our products, our sales volumes and our profits may be adversely affected. Industry Risks Future…
• FY2025 10-K: A summary of our equity-method investments, which were in operation as of December 31, 2025, is as follows: Entity Economic Interest River Bend Ag, LLC 50.0 % IFC S.A. 45.0 % Canpotex 36.2 % The summarized financial information shown below includes all non-consolidated companies carried on the equity method. Years…
• CF (CF INDUSTRIES HOLDINGS, INC.)
• FY2025 10-K: …2025-01-01 2025-12-31 0001324404 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-01-01 2025-12-31 0001324404 us-gaap:AccumulatedTranslationAdjustmentMember 2025-12-31 0001324404 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-12-31 0001324404…
• FY2025 10-K: …2024-12-31 0001324404 country:GB us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember cf:PooledDiversifiedFundsMember 2024-12-31 0001324404 country:GB us-gaap:PensionPlansDefinedBenefitMember cf:FixedIncomePooledUKGovernmentIndexLinkedSecuritiesMember 2024-12-31 0001324404 country:GB…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.